In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Myriad Sure To Appeal, Gene-Patent Case Casts Potential Shadows

Executive Summary

On March 29, Justice Robert Sweet of the Southern District Court of New York made the controversial decision to invalidate parts of seven patents owned by Myriad Genetics Inc. and the University of Utah Research Foundation, cheering opponents of the established practice of patenting gene sequences. It’s only the first step in a case that is almost certain to reach the US Supreme Court, but it might soon be eclipsed by a patent case currently before the Court, Bilski v. Kappos, which could have a much deeper effect on biotech business.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover the transcatheter heart valve market, clinical results on Eurocor's DIOR drug-eluting balloon, additions to Covidien's endomechanical business, and patent disputes in diagnostics.

PTO Creates Task Force To Respond To Upcoming Bilski Decision

PTO wants government to back Myriad in its appeal of gene patent ruling, agency's Arti Rai says at BIO IP conference. PTO seeks to reduce patent pendency through patent reform and a fast-track review option.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV003502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel